The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Arthritis Research & Therapy2011Vol. 13(4), pp. R115–R115
Citations Over TimeTop 1% of 2011 papers
Betty Chang, Min Huang, Michelle Francesco, Jun Chen, Jeremy Sokolove, Padmaja Magadala, William H. Robinson, Joseph J. Buggy
Abstract
PCI-32765 is efficacious in CIA, and in IC models that do not depend upon autoantibody production from B cells. Thus PCI-32765 targets not only B lymphocytes but also monocytes, macrophages and mast cells, which are important Btk-expressing effector cells in arthritis.
Related Papers
- → Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)(2013)217 cited
- → Potential applications of Bruton’s tyrosine kinase inhibitors for the prevention of allergic reactions(2017)21 cited
- → Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction.(1994)171 cited
- → Development of btk Transgenic Mice(1995)7 cited
- Molecular studies on Burton's tyrosine kinase(1999)